Board of Directors
Mr Sam Brougham, Non-Executive Chairman
Sam was appointed Chairman of the Board in July 2017. He has over thirty years’ experience in private and public investment and is currently a director of Ellerston Global Investments and Ceres Capital, a private global equity investment firm he co-founded in 1999. Sam also co-founded Structured Asset Management in 1993. After receiving an economics degree from the University of Adelaide, he spent his early career with Price Waterhouse, and as a partner at JB Were.
Dr Wayne Finlayson, Non-Executive Director
Wayne was appointed to the Board in June 2015. He is the primary inventor of Terragen’s microbiome technology platform. Wayne is currently the Managing Director and CEO of Servatus Biopharmaceuticals. He holds a BSc (Hons) and a PhD in organic chemistry and was a post-doctoral research fellow at the University of California, Berkeley, in the USA.
Mr Justus Homburg, Executive Director and CEO
Justus was appointed to the Board in June 2017 and assumed the role of CEO in July 2017. His thirty-year business career focused on commercialisation of new technologies in agriculture and human life sciences. Justus worked at Monsanto for nearly 15 years in roles of new technology development, strategic planning, corporate development, and general management. He has since held CEO roles with Progen Pharmaceuticals, Nestle Health Science’s Vital Foods and Chirogen Pharmaceutical Technologies. Justus completed undergraduate studies at Iowa State University, holds graduate degrees from Southern Illinois University and the University of Utrecht, was a University of Michigan faculty member and a Fulbright Scholar, and holds an MBA from the University of Washington.
Dr Gregory Robinson, Non-Executive Director
Greg was appointed to the Board in September 2012. He is currently the Chairman and CEO of Exablaze, an Australian manufacturer of the world's fastest computer networking equipment. Prior to this Greg worked in the Financial Services industry for more than 25 years. He has had exposure to Trading, Funds Management and Stockbroking. He served as Managing Director and CEO of Asia Pacific for ITG, a listed (NYSE:ITG) global quantitative stockbroker. Greg holds BSc (Hons) and PhD degrees in Physics from the University of Melbourne. He became a Member of the ASX in 1997. He is also a Fellow of the Financial Services Institute of Australia and a Member of the Australian Institute of Company Directors. He has undertaken business development in many parts of the globe, and has also managed businesses domiciled in Hong Kong, Singapore, Japan and the US.
Mr David Ryan, Non-Executive Director
David was appointed to the Board in August 2017. He has over 25 years’ experience in investment banking and is currently a Partner of Barbon Advisors LLP, a UK regulated corporate advisory boutique. Prior to this, David was a Managing Director at Goldman Sachs International where he worked for 20 years in a variety of roles in Asia and Europe, primarily in the Securities Division. During that period he became a partner with responsibility for managing the Asian Equities distribution business and then the European Equities business. Most recently David was Head of Institutional Wealth Management (Family Offices) for Goldman Sachs in Europe. In his early career David spent seven years at Macquarie Bank Limited in the Bullion and Commodities Division.
Dr Paul Schober, Non-Executive Director
Paul was appointed to the Board in June 2017. His 30-year career in the animal health industry includes senior executive positions in which he established global distribution agreements and implemented commercial rigour for biotechnology research companies including Peptech Animal Health, Anatara Lifesciences and Apex Laboratories. Paul attained PhD and MBA degrees at the University of Sydney.